.Pharmacolibrary.Drugs.ATC.L.L01XG03 .Pharmacolibrary.Drugs.ATC.L.L01XG03| name: | Ixazomib |
| ATC code: | L01XG03 | route: | oral |
| n-compartments | 3 |
Ixazomib is an oral proteasome inhibitor indicated for the treatment of multiple myeloma in combination with lenalidomide and dexamethasone in patients who have received at least one prior therapy. It is approved and currently used for this indication.
Population pharmacokinetics in adult patients with relapsed/refractory multiple myeloma; both sexes; typical age range 40-80 years. Parameters are representative of standard oral administration and are based on published studies.
Gupta, N, et al., & Venkatakrishnan, K (2019). Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clinical pharmacokinetics 58(4) 431–449. DOI:10.1007/s40262-018-0702-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30117017
Gupta, N, et al., & Venkatakrishnan, K (2017). Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clinical pharmacokinetics 56(11) 1355–1368. DOI:10.1007/s40262-017-0526-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28290121
Gupta, N, et al., & Nemunaitis, J (2016). The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. Journal of clinical pharmacology 56(10) 1288–1295. DOI:10.1002/jcph.719 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26872892